1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline and treatment characteristics of patients with-versus-without near-complete reperfusion (eTICI 2c–3)
Variable Near-Complete Reperfusion (n = 186) No Near-Complete Reperfusion (n = 224) P Value
Age (median) (IQR) (yr) 71.1 (61.2–80.1), n = 186 69.3 (58.4–79.6), n = 224 .12
Baseline NIHSS (median) (IQR) 18 (12–21), n = 186 17 (13–20), n = 224 .29
History of diabetes (No.) (%) 31/186 (16.7%) 46/224 (20.5%) .55
History of past stroke/TIA (No.) (%) 24/186 (12.9%) 33/224 (14.7%) .67
History of prior cardiac disease (No.) (%) 49/186 (26.3%) 47/224 (21.0%) .24
Baseline ASPECTS (median) (IQR) 8 (7–9), n = 186 8 (6–8), n = 224 .13
Collateral score (No.) (%) .06
 Poor 2/186 (1.1%) 11/218 (5.1%) 
 Moderate 154/186 (82.8%) 178/218 (81.7%) 
 Good 30/186 (16.1%) 29/218 (13.3%) 
Study drug to reperfusion time (median) (IQR) (min) 22 (9–39), n = 182 26 (12–52), n = 170 .17
Terminal ICA occlusion (No.) (%) 28/186 (15.1%) 44/223 (19.7%) .24
IV alteplase (No.) (%) 110/186 (59.1%) 122/224 (54.5%) .37
IV nerinetide (No.) (%) 89/186 (47.9%) 107/224 (47.8%) 1.00
Stent retriever as first-line device (No.) (%) 150/204 (73.5) 142/176 (80.7) .103
Carotid stent placement during EVT 22/110 (20.0) 12/81 (14.8) .445
Note:—IQR indicates interquartile range.